Product Description
ACI-7104 is an optimized vaccine formulation designed to induce a-syn-specific antibodies recognizing aggregated a-syn species that are toxic to neurons. (Sourced from: https://www.acimmune.com/pipeline/clinical-trials/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AC Immune
Company Location: 1015 LAUSANNE V8 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Spain
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACI-7104-PD-2103 | P2 |
Unknown Status |
Parkinson's Disease |
2028-01-31 |
|
VacSYn | P2 |
Recruiting |
Parkinson's Disease |
2028-01-01 |
32% |